

Claire N Harrison

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3933995/claire-n-harrison-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

168
papers

9,905
citations

43
h-index

98
g-index

185
ext. papers

11,907
ext. citations

6.1
avg, IF

5.88
L-index

#	Paper	IF	Citations
168	Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus.. <i>ESMO Open</i> , 2022 , 7, 100403	6	4
167	A prospective registry-based cohort study of the diagnosis and management of acute leukaemia in pregnancy: Study protocol.. <i>PLoS ONE</i> , 2022 , 17, e0263195	3.7	
166	A retrospective real-world study of the current treatment pathways for myelofibrosis in the United Kingdom: the REALISM UK study.. <i>Therapeutic Advances in Hematology</i> , 2022 , 13, 20406207221084487	5.7	
165	Addition of Navitoclax to Ongoing Ruxolitinib Therapy for Patients With Myelofibrosis With Progression or Suboptimal Response: Phase II Safety and Efficacy.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2102188	2.2	9
164	Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations.. <i>Lancet Haematology</i> , 2022 , 9, e301-e311	14.6	6
163	Diagnostic and management strategies for Myeloproliferative Neoplasm-Unclassifiable (MPN-U): An international survey of contemporary practice.. <i>Current Research in Translational Medicine</i> , 2022 , 70, 103338	3.7	0
162	Real-world tyrosine kinase inhibitor treatment pathways, monitoring patterns and responses in patients with chronic myeloid leukaemia in the United Kingdom: the UK TARGET CML study. <i>British Journal of Haematology</i> , 2021 , 192, 62-74	4.5	5
161	Does Early Intervention in Myelofibrosis Impact Outcomes? a Pooled Analysis of the Comfort I and II Studies. <i>Blood</i> , 2021 , 138, 1505-1505	2.2	0
160	Immune Checkpoint Analysis of T Effectors and Regulatory T Cells in Patients with CML Reveals Increased Expression at Diagnosis and with Refractory Disease. <i>Blood</i> , 2021 , 138, 2545-2545	2.2	
159	A Randomized, Phase 3 Trial of Fedratinib Versus Best Available Therapy in Patients with Intermediate-2 or High-Risk Myelofibrosis Previously Treated with Ruxolitinib (FREEDOM2). <i>Blood</i> , 2021 , 138, 3643-3643	2.2	2
158	Spleen and Symptom Responses with Fedratinib (FEDR) in Patients with Myelofibrosis (MF) and Substantial Splenomegaly. <i>Blood</i> , 2021 , 138, 2576-2576	2.2	
157	Safety and Tolerability of Fedratinib (FEDR), an Oral Inhibitor of Janus Kinase 2 (JAK2), in Patients with Intermediate- or High-Risk Myelofibrosis (MF) Previously Treated with Ruxolitinib (RUX): Results from the Phase 3b FREEDOM Trial. <i>Blood</i> , 2021 , 138, 389-389	2.2	4
156	Real-world survival of US patients with intermediate- to high-risk myelofibrosis: impact of ruxolitinib approval. <i>Annals of Hematology</i> , 2021 , 1	3	7
155	Clinicopathological characterisation of myeloproliferative neoplasm-unclassifiable (MPN-U): a retrospective analysis from a large UK tertiary referral centre. <i>British Journal of Haematology</i> , 2021 , 193, 792-797	4.5	1
154	Evidence of robust memory T-cell responses in patients with chronic myeloproliferative neoplasms following infection with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). <i>British Journal of Haematology</i> , 2021 , 193, 692-696	4.5	10
153	Patient-reported Effects of Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2, on Myelofibrosis-related Symptoms and Health-related Quality of Life in the Randomized, Placebo-controlled, Phase III JAKARTA Trial. <i>HemaSphere</i> , 2021 , 5, e553	0.3	1
152	MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic. <i>Future Oncology</i> , 2021 , 17, 1449-1458	3.6	11

151	provides a computational framework for the nonspecialist to profile high-dimensional cytometry data. <i>ELife</i> , 2021 , 10,	8.9	3
150	Direct oral anticoagulants for myeloproliferative neoplasms: results from an international study on 442 patients. <i>Leukemia</i> , 2021 , 35, 2989-2993	10.7	10
149	Single dose of BNT162b2 mRNA vaccine against SARS-CoV-2 induces high frequency of neutralising antibody and polyfunctional T-cell responses in patients with myeloproliferative neoplasms. <i>Leukemia</i> , 2021 , 35, 3573-3577	10.7	26
148	Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) induces neutralising antibody and polyfunctional T-cell responses in patients with chronic myeloid leukaemia. <i>British Journal of Haematology</i> , 2021 , 194, 999-1006	4.5	24
147	Large Scale Internet-based Survey of Patients With a Myeloproliferative Neoplasm: Opinions and Experiences Regarding SARS-CoV-2 (COVID-19) Vaccination Strategies in 2021. <i>HemaSphere</i> , 2021 , 5, e609	0.3	1
146	Updated results of the placebo-controlled, phase III JAKARTA trial of fedratinib in patients with intermediate-2 or high-risk myelofibrosis. <i>British Journal of Haematology</i> , 2021 , 195, 244-248	4.5	7
145	Hydroxycarbamide effects on DNA methylation and gene expression in myeloproliferative neoplasms. <i>Genome Research</i> , 2021 , 31, 1381-1394	9.7	1
144	Altered immune response to the annual influenza A vaccine in patients with myeloproliferative neoplasms. <i>British Journal of Haematology</i> , 2021 , 193, 150-154	4.5	8
143	High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib. <i>Leukemia</i> , 2021 , 35, 485-493	10.7	45
142	Current and future status of JAK inhibitors. <i>Lancet, The</i> , 2021 , 398, 803-816	4.0	17
141	Unmet clinical needs in the management of CALR-mutated essential thrombocythaemia: a consensus-based proposal from the European LeukemiaNet. <i>Lancet Haematology, the</i> , 2021 , 8, e658-e665	14.6	4
140	Current and future therapies for myelofibrosis. <i>Blood Reviews</i> , 2020 , 42, 100715	11.1	7
139	How we manage Philadelphia-negative myeloproliferative neoplasms in pregnancy. <i>British Journal of Haematology</i> , 2020 , 189, 625-634	4.5	20
138	Management of myelofibrosis after ruxolitinib failure. <i>Annals of Hematology</i> , 2020 , 99, 1177-1191	3	29
137	Forging ahead or moving back: dilemmas and disappointments of novel agents for myeloproliferative neoplasms. <i>British Journal of Haematology</i> , 2020 , 191, 21-36	4.5	3
136	Current and future role of fedratinib in the treatment of myelofibrosis. <i>Future Oncology</i> , 2020 , 16, 175-186	3.6	7
135	Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKARTA2 study using stringent criteria for ruxolitinib failure. <i>American Journal of Hematology</i> , 2020 , 95, 594-603	7.1	45
134	A physician survey on the application of the British Society for Haematology guidelines for the diagnosis and management of myelofibrosis in the UK. <i>British Journal of Haematology</i> , 2020 , 188, e105-e109	4.5	0

133	Outcomes of patients receiving direct oral anticoagulants for myeloproliferative neoplasm-associated venous thromboembolism in a large tertiary centre in the UK. <i>British Journal of Haematology</i> , 2020 , 189, e79-e81	4.5	18
132	Bone marrow niche dysregulation in myeloproliferative neoplasms. <i>Haematologica</i> , 2020 , 105, 1189-1206	6.6	9
131	A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat Versus Best Available Therapy (BAT) in Patients with Intermediate-2 or High-Risk Myelofibrosis (MF) Refractory to Janus Kinase (JAK) Inhibitor. <i>Blood</i> , 2020 , 136, 43-44	2.2	
130	The Addition of Navitoclax to Ruxolitinib Demonstrates Efficacy within Different High-Risk Populations in Patients with Relapsed/Refractory Myelofibrosis. <i>Blood</i> , 2020 , 136, 49-50	2.2	15
129	Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2 (JAK2), in Patients with Intermediate-2 or High-Risk Myelofibrosis (MF): Updated Results from the Randomized, Placebo-Controlled, Phase III JAKARTA Trial. <i>Blood</i> , 2020 , 136, 10-12	2.2	2
128	Phazar: A Phase Ib Study to Assess the Safety and Tolerability of Ruxolitinib in Combination with Azacitidine in Advanced Phase Myeloproliferative Neoplasms (MPN), Including Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukaemia (AML) Arising from MPN [ISRCTN16783472]. <i>Blood</i> , 2020 , 136, 23-28	2.2	3
127	The BET Inhibitor, CPI-0610, Promotes Myeloid Differentiation in Myelofibrosis Patient Bone Marrow and Peripheral CD34+ Hematopoietic Stem Cells. <i>Blood</i> , 2020 , 136, 37-38	2.2	1
126	Real-World Survival Among Patients with Intermediate- to High-Risk Myelofibrosis in the United States: Impact of Ruxolitinib Approval. <i>Blood</i> , 2020 , 136, 46-47	2.2	4
125	MANIFEST-2, a Global, Phase 3, Randomized, Double-Blind, Active-Control Study of CPI-0610 and Ruxolitinib Vs. Placebo and Ruxolitinib in JAK-Inhibitor-Naive Myelofibrosis Patients. <i>Blood</i> , 2020 , 136, 43-43	2.2	10
124	Splanchnic vein thromboses associated with myeloproliferative neoplasms: An international, retrospective study on 518 cases. <i>American Journal of Hematology</i> , 2020 , 95, 156-166	7.1	27
123	Depressive symptoms and myeloproliferative neoplasms: Understanding the confounding factor in a complex condition. <i>Cancer Medicine</i> , 2020 , 9, 8301-8309	4.8	5
122	Safety and efficacy of the combination of sonidegib and ruxolitinib in myelofibrosis: a phase 1b/2 dose-finding study. <i>Blood Advances</i> , 2020 , 4, 3063-3071	7.8	3
121	Characteristics and outcomes of patients with essential thrombocythemia or polycythemia vera diagnosed before 20 years of age: a systematic review. <i>Haematologica</i> , 2019 , 104, 1580-1588	6.6	22
120	Facing erythrocytosis: Results of an international physician survey. <i>American Journal of Hematology</i> , 2019 , 94, E225-E227	7.1	5
119	Essential thrombocythaemia treated with recombinant interferon: Real world United Kingdom referral centre experience. <i>British Journal of Haematology</i> , 2019 , 186, 561-564	4.5	5
118	UK results from the myeloproliferative neoplasms (MPN) landmark survey on the symptom, emotional and economic burden of MPN. <i>British Journal of Haematology</i> , 2019 , 186, e1-e4	4.5	4
117	State-of-the-art review: allogeneic stem cell transplantation for myelofibrosis in 2019. <i>Haematologica</i> , 2019 , 104, 659-668	6.6	40
116	A Phase 2 Study of Luspatercept in Patients with Myelofibrosis-Associated Anemia. <i>Blood</i> , 2019 , 134, 557-557	2.2	35

115	MANIFEST, a Phase 2 Study of CPI-0610, a Bromodomain and Extraterminal Domain Inhibitor (BETi), As Monotherapy or "Add-on" to Ruxolitinib, in Patients with Refractory or Intolerant Advanced Myelofibrosis. <i>Blood</i> , 2019 , 134, 670-670	2.2	30
114	Preliminary Report of MANIFEST, a Phase 2 Study of CPI-0610, a Bromodomain and Extraterminal Domain Inhibitor (BETi), in Combination with Ruxolitinib, in JAK Inhibitor (JAKi) Treatment Naïve Myelofibrosis Patients. <i>Blood</i> , 2019 , 134, 4164-4164	2.2	17
113	Results from a Phase 2 Study of Navitoclax in Combination with Ruxolitinib in Patients with Primary or Secondary Myelofibrosis. <i>Blood</i> , 2019 , 134, 671-671	2.2	30
112	The poor outcome in high molecular risk, hydroxycarbamide-resistant/intolerant ET is not ameliorated by ruxolitinib. <i>Blood</i> , 2019 , 134, 2107-2111	2.2	9
111	EXPAND, a dose-finding study of ruxolitinib in patients with myelofibrosis and low platelet counts: 48-week follow-up analysis. <i>Haematologica</i> , 2019 , 104, 947-954	6.6	22
110	A guideline for the management of specific situations in polycythaemia vera and secondary erythrocytosis: A British Society for Haematology Guideline. <i>British Journal of Haematology</i> , 2019 , 184, 161-175	4.5	47
109	A guideline for the diagnosis and management of polycythaemia vera. A British Society for Haematology Guideline. <i>British Journal of Haematology</i> , 2019 , 184, 176-191	4.5	60
108	Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis: A Randomized Clinical Trial. <i>JAMA Oncology</i> , 2018 , 4, 652-659	13.4	133
107	Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. <i>Leukemia</i> , 2018 , 32, 1057-1069	10.7	263
106	Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial. <i>Lancet Haematology</i> , 2018 , 5, e73-e81	14.6	115
105	An updated review of the JAK1/2 inhibitor (ruxolitinib) in the Philadelphia-negative myeloproliferative neoplasms. <i>Future Oncology</i> , 2018 , 14, 137-150	3.6	8
104	Impact on MPN Symptoms and Quality of Life of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia: Results of Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial. <i>Blood</i> , 2018 , 132, 577-577	2.2	6
103	Results of the Myeloproliferative Neoplasms - Research Consortium (MPN-RC) 112 Randomized Trial of Pegylated Interferon Alfa-2a (PEG) Versus Hydroxyurea (HU) Therapy for the Treatment of High Risk Polycythemia Vera (PV) and High Risk Essential Thrombocythemia (ET). <i>Blood</i> , 2018 , 132, 577-577	2.2	32
102	Results from the Myeloproliferative Neoplasm Patient Care Survey: Patient Care Opportunities and Challenges. <i>Blood</i> , 2018 , 132, 4289-4289	2.2	1
101	Longitudinal Mutational Analysis in Hydroxycarbamide-Resistant/Intolerant Essential Thrombocythemia Treated on the Majic-ET Study. <i>Blood</i> , 2018 , 132, 1784-1784	2.2	
100	Myeloproliferative Neoplasms in Patients below 25 Years Old at Diagnosis: A Retrospective International Cooperative Work. <i>Blood</i> , 2018 , 132, 1759-1759	2.2	
99	SOHO State-of-the-Art Update and Next Questions: MPN. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018 , 18, 1-12	2	4
98	Shortened telomeres in essential thrombocythemia: clinicopathological and treatment correlations. <i>Haematologica</i> , 2018 , 103, e234-e236	6.6	2

97	Treatment of essential thrombocythemia in Europe: a prospective long-term observational study of 3649 high-risk patients in the Evaluation of Anagrelide Efficacy and Long-term Safety study. <i>Haematologica</i> , 2018 , 103, 51-60	6.6	39
96	Comprehensive haematological control with ruxolitinib in patients with polycythaemia vera resistant to or intolerant of hydroxycarbamide. <i>British Journal of Haematology</i> , 2018 , 182, 279-284	4.5	1
95	Hb Baden: a rare high affinity haemoglobin variant and its management. <i>Journal of Clinical Pathology</i> , 2018 , 71, 79-80	3.9	2
94	Hydroxycarbamide Plus Aspirin Versus Aspirin Alone in Patients With Essential Thrombocythemia Age 40 to 59 Years Without High-Risk Features. <i>Journal of Clinical Oncology</i> , 2018 , 36, 3361-3369	2.2	32
93	Ruxolitinib for the Treatment of Essential Thrombocythemia. <i>HemaSphere</i> , 2018 , 2, e56	0.3	5
92	Classification and Personalized Prognosis in Myeloproliferative Neoplasms. <i>New England Journal of Medicine</i> , 2018 , 379, 1416-1430	59.2	256
91	What is pre-fibrotic myelofibrosis and how should it be managed in 2018?. <i>British Journal of Haematology</i> , 2018 , 183, 23-34	4.5	9
90	Markers of iron deficiency in patients with polycythemia vera receiving ruxolitinib or best available therapy. <i>Leukemia Research</i> , 2017 , 56, 52-59	2.7	13
89	Managing side effects of JAK inhibitors for myelofibrosis in clinical practice. <i>Expert Review of Hematology</i> , 2017 , 10, 617-625	2.8	21
88	Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study. <i>Lancet Haematology</i> , 2017 , 4, e317-e324	14.6	148
87	Ruxolitinib, a potent JAK1/JAK2 inhibitor, induces temporary reductions in the allelic burden of concurrent mutations in chronic neutrophilic leukemia. <i>Haematologica</i> , 2017 , 102, e238-e240	6.6	31
86	Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial. <i>Lancet Haematology</i> , 2017 , 4, e225-e236	14.6	137
85	Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses. <i>Journal of Hematology and Oncology</i> , 2017 , 10, 156	22.4	137
84	A discussion of blood cancers and the MPN landmark survey. <i>International Journal of Hematologic Oncology</i> , 2017 , 6, 101-104	1	
83	Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide. <i>Blood</i> , 2017 , 130, 1889-1897	2.2	101
82	The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN Landmark survey. <i>Annals of Hematology</i> , 2017 , 96, 1653-1665	3	49
81	Is there a role for pomalidomide in the treatment of myelofibrosis?. <i>Expert Opinion on Orphan Drugs</i> , 2016 , 4, 501-509	1.1	
80	Antiplatelet therapy versus observation in low-risk essential thrombocythemia with a CALR mutation. <i>Haematologica</i> , 2016 , 101, 926-31	6.6	91

79	Symptomatic Profiles of Patients With Polycythemia Vera: Implications of Inadequately Controlled Disease. <i>Journal of Clinical Oncology</i> , 2016 , 34, 151-9	2.2	42
78	How We Identify and Manage Patients with Inadequately Controlled Polycythemia Vera. <i>Current Hematologic Malignancy Reports</i> , 2016 , 11, 356-67	4.4	10
77	Symptom Burden As Primary Driver for Therapy in Patients with Myelofibrosis: An Analysis By MPN International Quality of Life Study Group. <i>Blood</i> , 2016 , 128, 3117-3117	2.2	4
76	Interim Analysis of the Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia. <i>Blood</i> , 2016 , 128, 479-479	2.2	20
75	Disease characteristics and outcomes in younger adults with primary and secondary myelofibrosis. <i>British Journal of Haematology</i> , 2016 , 175, 37-42	4.5	6
74	Management of polycythaemia vera: a critical review of current data. <i>British Journal of Haematology</i> , 2016 , 172, 337-49	4.5	18
73	Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial. <i>Haematologica</i> , 2016 , 101, 821-9	6.6	115
72	Pegylated interferon alpha-2a for essential thrombocythemia during pregnancy: outcome and safety. A case series. <i>Haematologica</i> , 2016 , 101, e182-4	6.6	36
71	Pregnancy outcomes in myeloproliferative neoplasms: UK prospective cohort study. <i>British Journal of Haematology</i> , 2016 , 175, 31-6	4.5	45
70	Ruxolitinib is effective in patients with intermediate-1 risk myelofibrosis: a summary of recent evidence. <i>Leukemia and Lymphoma</i> , 2016 , 57, 2259-67	1.9	13
69	Pacritinib: a new agent for the management of myelofibrosis?. <i>Expert Opinion on Pharmacotherapy</i> , 2015 , 16, 2381-90	4	6
68	Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis: A Randomized Clinical Trial. <i>JAMA Oncology</i> , 2015 , 1, 643-51	13.4	242
67	How we diagnose and treat essential thrombocythaemia. <i>British Journal of Haematology</i> , 2015 , 171, 306-23	4.5	12
66	JAK inhibition induces silencing of T Helper cytokine secretion and a profound reduction in T regulatory cells. <i>British Journal of Haematology</i> , 2015 , 171, 60-73	4.5	59
65	Immunological Consequences of JAK Inhibition: Friend or Foe?. <i>Current Hematologic Malignancy Reports</i> , 2015 , 10, 370-9	4.4	56
64	How We Treat Myeloproliferative Neoplasms. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015 , 15 Suppl, S19-26	2	
63	Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms. <i>Nature Communications</i> , 2015 , 6, 6691	17.4	120
62	Targeting of the Hedgehog pathway in myeloid malignancies: still a worthy chase?. <i>British Journal of Haematology</i> , 2015 , 170, 323-35	4.5	12

61	A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis. <i>Haematologica</i> , 2015 , 100, 1139-45	6.6	151
60	Essential thrombocythaemia. <i>Hematology</i> , 2015 , 20, 119-20	2.2	
59	Effect of mutation order on myeloproliferative neoplasms. <i>New England Journal of Medicine</i> , 2015 , 372, 601-612	59.2	334
58	Ruxolitinib versus standard therapy for the treatment of polycythemia vera. <i>New England Journal of Medicine</i> , 2015 , 372, 426-35	59.2	533
57	Phase 1b/2 Study of the Efficacy and Safety of Sonidegib (LDE225) in Combination with Ruxolitinib (INC424) in Patients with Myelofibrosis. <i>Blood</i> , 2015 , 126, 825-825	2.2	22
56	How many JAK inhibitors in myelofibrosis?. <i>Best Practice and Research in Clinical Haematology</i> , 2014 , 27, 187-95	4.2	5
55	Modification of British Committee for Standards in Haematology diagnostic criteria for essential thrombocythaemia. <i>British Journal of Haematology</i> , 2014 , 167, 421-3	4.5	30
54	Treatment of thromboembolic events coincident with the diagnosis of myeloproliferative neoplasms: a physician survey. <i>Thrombosis Research</i> , 2014 , 134, 251-4	8.2	27
53	Comparison of placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT studies. <i>Haematologica</i> , 2014 , 99, 292-8	6.6	35
52	Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients. <i>Blood</i> , 2014 , 123, 3803-10	2.2	65
51	Orphan drugs for myelofibrosis. <i>Expert Opinion on Orphan Drugs</i> , 2014 , 2, 391-405	1.1	1
50	Safety evaluation of ruxolitinib for treating myelofibrosis. <i>Expert Opinion on Drug Safety</i> , 2014 , 13, 967-76	4.1	19
49	Use of JAK inhibitors in the management of myelofibrosis: a revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012. <i>British Journal of Haematology</i> , 2014 , 167, 418-20	4.5	30
48	Update in the myeloproliferative neoplasms. <i>Clinical Medicine</i> , 2014 , 14 Suppl 6, s66-70	1.9	
47	A phase 1b, dose-finding study of ruxolitinib plus panobinostat in patients with myelofibrosis.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 7022-7022	2.2	3
46	A phase II study of vorinostat (MK-0683) in patients with polycythemia vera and essential thrombocythaemia. <i>British Journal of Haematology</i> , 2013 , 162, 498-508	4.5	58
45	Practical management of patients with myelofibrosis receiving ruxolitinib. <i>Expert Review of Hematology</i> , 2013 , 6, 511-23	2.8	24
44	Molecular classification of myeloproliferative neoplasms-pros and cons. <i>Current Hematologic Malignancy Reports</i> , 2013 , 8, 342-50	4.4	3

43	Revised response criteria for myelofibrosis: International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) and European LeukemiaNet (ELN) consensus report. <i>Blood</i> , 2013 , 122, 1395-8	2.2	218
42	Cytoreductive treatment patterns for essential thrombocythemia in Europe. Analysis of 3643 patients in the EXELS study. <i>Leukemia Research</i> , 2013 , 37, 162-8	2.7	22
41	Molecular diagnosis of the myeloproliferative neoplasms: UK guidelines for the detection of JAK2 V617F and other relevant mutations. <i>British Journal of Haematology</i> , 2013 , 160, 25-34	4.5	68
40	Health-related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy. <i>British Journal of Haematology</i> , 2013 , 162, 229-39	4.5	60
39	Combination therapies in Myeloproliferative Neoplasms: why do we need them and how to identify potential winners?. <i>Journal of Cellular and Molecular Medicine</i> , 2013 , 17, 1410-4	5.6	3
38	Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project. <i>Blood</i> , 2013 , 121, 4778-81	2.2	159
37	Janus kinase inhibition and its effect upon the therapeutic landscape for myelofibrosis: from palliation to cure?. <i>British Journal of Haematology</i> , 2012 , 157, 426-37	4.5	18
36	Guideline for the diagnosis and management of myelofibrosis. <i>British Journal of Haematology</i> , 2012 , 158, 453-71	4.5	76
35	JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. <i>New England Journal of Medicine</i> , 2012 , 366, 787-98	59.2	1232
34	Ruxolitinib: a potent and selective Janus kinase 1 and 2 inhibitor in patients with myelofibrosis. An update for clinicians. <i>Therapeutic Advances in Hematology</i> , 2012 , 3, 341-54	5.7	36
33	Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. <i>Journal of Clinical Oncology</i> , 2012 , 30, 4098-103	2.2	252
32	A Randomised Comparison of Clofarabine Versus Low Dose Ara-C As First Line Treatment for Older Patients with AML. <i>Blood</i> , 2012 , 120, 889-889	2.2	1
31	Myeloproliferative disorders in pregnancy. <i>Hematology/Oncology Clinics of North America</i> , 2011 , 25, 261-75, vii	3.1	22
30	The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients. <i>Blood</i> , 2011 , 118, 401-8	2.2	215
29	Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. <i>Journal of Clinical Oncology</i> , 2011 , 29, 761-70	2.2	589
28	The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) Derived Total Symptom Score (TSS): An International Trial of 1433 Patients with Myeloproliferative Neoplasms (MPNs)., <i>Blood</i> , 2011 , 118, 3839-3839	2.2	4
27	The Addition of Gemtuzumab Ozogamicin to Intensive Chemotherapy in Older Patients with AML Produces a Significant Improvement in Overall Survival: Results of the UK NCRI AML16 Randomized Trial. <i>Blood</i> , 2011 , 118, 582-582	2.2	7
26	A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process. <i>British Journal of Haematology</i> , 2010 , 148, 961-3	4.5	115

25	Guideline for investigation and management of adults and children presenting with a thrombocytosis. <i>British Journal of Haematology</i> , 2010 , 149, 352-75	4.5	209
24	Rethinking disease definitions and therapeutic strategies in essential thrombocythemia and polycythemia vera. <i>Hematology American Society of Hematology Education Program</i> , 2010 , 2010, 129-34	3.1	17
23	Reply to J. Thiele et al. <i>Journal of Clinical Oncology</i> , 2009 , 27, e222-e223	2.2	7
22	Do we know more about essential thrombocythemia because of JAK2V617F?. <i>Current Hematologic Malignancy Reports</i> , 2009 , 4, 25-32	4.4	1
21	The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis. <i>Leukemia Research</i> , 2009 , 33, 1199-203	2.7	173
20	Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes. <i>Blood</i> , 2008 , 111, 60-70	2.2	187
19	Amendment to the guideline for diagnosis and investigation of polycythaemia/erythrocytosis. <i>British Journal of Haematology</i> , 2007 , 138, 821-2	4.5	90
18	JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. <i>New England Journal of Medicine</i> , 2007 , 356, 459-68	59.2	996
17	Clinical Significance of MPL Mutations in Essential Thrombocythemia: Analysis of the PT-1 Cohort.. <i>Blood</i> , 2007 , 110, 677-677	2.2	3
16	Impact of Platelet Glycoprotein Polymorphisms upon Clinical Events in Essential Thrombocythaemia Patients Enrolled in the PT1 Trial.. <i>Blood</i> , 2007 , 110, 2543-2543	2.2	
15	Management of essential thrombocythemia: implications of the medical research council primary thrombocythemia 1 trial. <i>Seminars in Thrombosis and Hemostasis</i> , 2006 , 32, 283-8	5.3	3
14	Myeloproliferative Disorders Are Associated with an Increase in Levels of Prothrombotic and Inflammatory Markers Despite Cytoreductive Therapy.. <i>Blood</i> , 2006 , 108, 3625-3625	2.2	
13	Natural History of Idiopathic Erythrocytosis I A Retrospective Case Series Review.. <i>Blood</i> , 2006 , 108, 1298-1298	2.2	
12	Mechanism of thrombosis in essential thrombocythaemia. <i>Haematologica</i> , 2006 , 91, 145b	6.6	
11	Pregnancy and its management in the Philadelphia negative myeloproliferative diseases. <i>British Journal of Haematology</i> , 2005 , 129, 293-306	4.5	101
10	Guidelines for the diagnosis, investigation and management of polycythaemia/erythrocytosis. <i>British Journal of Haematology</i> , 2005 , 130, 174-95	4.5	264
9	Essential thrombocythaemia: challenges and evidence-based management. <i>British Journal of Haematology</i> , 2005 , 130, 153-65	4.5	75
8	Anagrelide for control of thrombocytosis due to myeloproliferative disorders. <i>Future Oncology</i> , 2005 , 1, 609-18	3.6	4

7	The Presence of the V617F Mutation Is Associated with Higher Haemoglobin, Older Age and an Increased Risk of Thrombosis in Essential Thrombocythemia.. <i>Blood</i> , 2005 , 106, 3531-3531	2.2	
6	The Use of the PFA-100 and Thromboelastograph in Assessing Haemostasis and Drug Efficacy in Essential Thrombocythemia.. <i>Blood</i> , 2005 , 106, 4959-4959	2.2	
5	The management and outcome of 18 pregnancies in women with polycythemia vera. <i>Haematologica</i> , 2005 , 90, 1477-83	6.6	41
4	Clonality in essential thrombocythaemia. <i>Laboratory Hematology: Official Publication of the International Society for Laboratory Hematology</i> , 2004 , 10, 184-7		1
3	Essential thrombocythemia. <i>Hematology/Oncology Clinics of North America</i> , 2003 , 17, 1175-90, vii	3.1	23
2	Current trends in essential thrombocythaemia. <i>British Journal of Haematology</i> , 2002 , 117, 796-808	4.5	36
1	Single dose of BNT162b2 mRNA vaccine against SARS-CoV-2 induces high frequency of neutralising antibody and polyfunctional T-cell responses in patients with myeloproliferative neoplasms		1